Ferumoxytol
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Ferumoxytol: From Iron Deficiency (IV Iron Replacement) to Plummer-Vinson Syndrome
One-Sentence Summary
Ferumoxytol is an intravenous iron-replacement agent whose superparamagnetic iron oxide nanoparticle structure also makes it usable as an MRI contrast agent; no formal original-indication record or mechanism-of-action detail was provided in this evidence pack. The TxGNN model predicts potential efficacy for Plummer-Vinson Syndrome, but currently no clinical trials and no published literature support this specific prediction — it is a model-only inference (Evidence Level L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (drug not marketed in Taiwan/US; 0 licenses on file) |
| Predicted New Indication | Plummer-Vinson syndrome |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on the information that is available, ferumoxytol is characterized as an IV iron-replacement agent (superparamagnetic iron oxide nanoparticles), a class whose established pharmacology is correcting iron deficiency.
Plummer-Vinson syndrome is a disorder whose pathology is strongly associated with iron-deficiency anemia, so there is a class-level rationale that an IV iron agent could theoretically address the underlying iron deficiency component of the syndrome.
However, this link is purely a pharmacological-class-level inference, not a mechanism study specific to Plummer-Vinson syndrome. No clinical trial or literature evidence currently tests or supports this specific application, so the mechanistic plausibility remains unverified.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Not marketed in Taiwan or the US; no license records are available for this drug.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an Evidence Level L5 prediction — model output only, with zero clinical trials or literature specifically linking ferumoxytol to Plummer-Vinson syndrome. In addition, a Blocking data gap (DG001: missing TFDA label warnings/contraindications) means the safety screen (S1) cannot even begin.
To proceed, the following is needed:
- TFDA package insert data — warnings and contraindications (Blocking gap DG001)
- Detailed original mechanism-of-action data (High-priority gap DG002)
- Preclinical or mechanistic evidence specific to Plummer-Vinson syndrome, beyond the current class-level iron-deficiency inference
- Route compatibility assessment (currently unassessed/pending)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.